Polypoidal Choroidal Vasculopathy
37
3
3
21
Key Insights
Highlights
Success Rate
95% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
2.7%
1 terminated out of 37 trials
95.5%
+8.9% vs benchmark
32%
12 trials in Phase 3/4
38%
8 of 21 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 21 completed trials
Clinical Trials (37)
Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO)
Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial
Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment
Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV)
OCT in Rare Chorioretinal Diseases
Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV
Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy
Clinical Implication of Aflibercept in PCV Treatment in China
Conbercept for Polypoidal Choroidal Vasculopathy（START Study）
An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy
OCTA and Polypoidal Choroidal Vasculopathy
Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept
Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy
Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy
Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy
Biomarkers of Common Eye Diseases
Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy
Initial Versus Delayed PDT Combination With Conbercept in PCV
Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT)
Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy